GLP-1 receptor agonists × body weight & composition

TrialInternational journal of obesity (2005)2016

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

A Blackman et al.PubMed ↗Full text ↗Publisher ↗

  • Liraglutide 3.0 mglooks good hereLower percentage weight loss.Randomised, small.

What the trial testedrandomised · 359 people · 2016

Randomised vs placebo

Probably lowered percentage weight loss

−4.20percentage points−5.20 to −3.10

liraglutide 3.0 mg vs placebo

As reported

difference −4.2 %, 95% CI −5.20 to −3.10 · the paper's word: mean percentage weight loss

Who was studied, and how

359people with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide 3.0 mg
placebo

Probably lowered percentage weight loss−4.20

randomised

the abstract, start to end

-1.6%, estimated treatment difference: -4.2% (95% CI, -5.2 to -3.1%),

← favours treatmentfavours comparator →
could be chance
Mean percentage weight lossliraglutide 3.0 mg vs placebo
−4.2−5.20 to −3.10
GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

232 papers cite itlatest 60 shown

2016
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 27005405